Business
STAAR Surgical Announces Expiration of "Window Shop" Period; No Competing Acquisition Proposals Received
LAKE FOREST, Calif., September 22, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day "window shop" period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The "window shop" period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was recei
About this update from Alcon Ag
[{"type":"text","content":"Reinforces STAAR Board’s Determination that Alcon Merger Maximizes Stockholder Value and is Best Path Forward for STAAR Stockholders","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"LAKE FOREST, Calif., September 22, 2025--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day "window shop" period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The "window shop" period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was received despite Broadwood Partners’ active exploration of alternative buyers over the past 45 days.","length":632,"tagName":"p"},{"type":"text","content":""The expiration of the ‘window shop’ period with no competing acquisition proposal reinforces the Board’s conclusion that the Alcon merger maximizes value for STAAR stockholders," said Stephen Farrell, CEO of STAAR. "In an effort to derail the Alcon merger, Broadwood Partners has repeatedly claimed that other parties are interested and capable of making a proposal. However, the Company has not received any competing proposal since media reports of takeover interest in STAAR first surfaced in July 2024, nor since the Alcon merger agreement was announced."","length":580,"tagName":"p"},{"type":"text","content":""Broadwood has provided significant input on the composition of the STAAR Board and management team, including recommending three of the Board’s current six members and voting for all of STAAR’s directors at STAAR’s 2025 Annual Meeting. The Board extensively considered Broadwood’s opposition to the Alcon merger agreement as well as its fiduciary responsibility to all stockholders, including Broadwood, before unanimously approving the Alcon agreement. Collectively, the Board and management team understand the market risks, trends, and opportunities better than Broadwood, and Broadwood’s opposition to the transaction is unfounded," continued Mr. Farrell.","length":670,"tagName":"p"},{"type":"text","content":"STAAR stockholders are encouraged to consider the following additional facts:","length":77,"tagName":"p"},{"type":"list...